LCTX Lineage Cell Therapeutics Inc
Price (delayed)
$0.4372
Market cap
$99.84M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.09
Enterprise value
$56.56M
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage's programs are based on its robust proprietary cell-based therapy platform and associated in-house
Highlights
Lineage Cell Therapeutics's quick ratio has surged by 72% YoY and by 45% QoQ
LCTX's EPS is up by 25% year-on-year and by 18% since the previous quarter
Key stats
What are the main financial stats of LCTX
Market
Valuations
Earnings
Shares outstanding
228.36M
Market cap
$99.84M
Enterprise value
$56.56M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.05
Price to sales (P/S)
9.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.95
Revenue
$9.5M
Gross profit
$9.17M
Operating income
-$21.48M
Net income
-$18.61M
EBIT
-$18.61M
EBITDA
-$18M
Free cash flow
-$23.66M
Per share
Balance sheet
Liquidity
EPS
-$0.09
EPS diluted
-$0.09
Free cash flow per share
-$0.12
Book value per share
$0.42
Revenue per share
$0.05
TBVPS
$0.28
Total assets
$113.22M
Total liabilities
$36.21M
Debt
$2.51M
Equity
$78.38M
Working capital
$37.02M
Debt to equity
0.03
Current ratio
3.65
Quick ratio
3.47
Net debt/EBITDA
2.4
Margins
Efficiency
Dividend
EBITDA margin
-189.5%
Gross margin
96.5%
Net margin
-195.9%
Operating margin
-226.1%
Return on assets
-17.7%
Return on equity
-26.1%
Return on invested capital
N/A
Return on capital employed
-18.8%
Return on sales
-195.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LCTX stock price
How has the Lineage Cell Therapeutics stock price performed over time
Intraday
6.37%
1 week
-12.58%
1 month
-22.14%
1 year
-68.77%
YTD
-13%
QTD
-3.19%
Financial performance
How have Lineage Cell Therapeutics's revenue and profit performed over time
Revenue
$9.5M
Gross profit
$9.17M
Operating income
-$21.48M
Net income
-$18.61M
Gross margin
96.5%
Net margin
-195.9%
The net margin has grown by 18% YoY and by 15% from the previous quarter
LCTX's operating margin is up by 18% year-on-year and by 13% since the previous quarter
The company's net income rose by 13% YoY and by 7% QoQ
The operating income has increased by 13% year-on-year and by 6% since the previous quarter
Growth
What is Lineage Cell Therapeutics's growth rate over time
Valuation
What is Lineage Cell Therapeutics stock price valuation
P/E
N/A
P/B
1.05
P/S
9.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.95
LCTX's EPS is up by 25% year-on-year and by 18% since the previous quarter
LCTX's P/B is 66% below its 5-year quarterly average of 2.9 and 62% below its last 4 quarters average of 2.6
LCTX's equity is up by 24% YoY and by 18% QoQ
LCTX's price to sales (P/S) is 86% less than its 5-year quarterly average of 62.6 and 63% less than its last 4 quarters average of 23.6
The revenue has grown by 9% from the previous quarter and by 6% YoY
Efficiency
How efficient is Lineage Cell Therapeutics business performance
LCTX's ROS is up by 25% year-on-year and by 15% since the previous quarter
LCTX's return on equity is up by 17% year-on-year and by 12% since the previous quarter
Lineage Cell Therapeutics's ROA has increased by 11% YoY and by 10% from the previous quarter
Dividends
What is LCTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LCTX.
Financial health
How did Lineage Cell Therapeutics financials performed over time
Lineage Cell Therapeutics's quick ratio has surged by 72% YoY and by 45% QoQ
The current ratio has surged by 71% year-on-year and by 47% since the previous quarter
The debt is 97% less than the equity
The debt to equity has contracted by 40% YoY and by 25% from the previous quarter
LCTX's equity is up by 24% YoY and by 18% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.